Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tapering of adalimumab or secukinumab in ankylosing spondylitis
ChiCTR2300071073Phase 4Not yet recruiting
- Sponsor
- Tongji Hospital
- Start
- May 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of adalimumab and secukinumab in ankylosing spondylitis (AS) (2 arms), sponsored by Tongji Hospital. Primary endpoint: Recurrence rate. Planned start May 2023; status: not yet recruiting.
02
Drugs
adalimumabsecukinumab
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on ChiCTR2300071073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300071073.